<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND PURPOSE: We studied whether the inducible nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> synthase (iNOS) inhibitor <z:chebi fb="0" ids="40618">aminoguanidine</z:chebi> reduces focal cerebral ischemic damage in a relatively noninvasive <z:hpo ids='HP_0001297'>stroke</z:hpo> model in which the rat middle cerebral artery (<z:chebi fb="70" ids="34342">MCA</z:chebi>) is occluded using an intravascular filament </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: In rats anesthetized with <z:chebi fb="2" ids="5615">halothane</z:chebi>, a nylon filament was advanced into the internal carotid artery until its tip occluded the origin of the <z:chebi fb="70" ids="34342">MCA</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>The filament was left in place for 2 hours and then withdrawn </plain></SENT>
<SENT sid="3" pm="."><plain>Twenty-four hours later, rats received intraperitoneal injections of <z:chebi fb="0" ids="40618">aminoguanidine</z:chebi> (100 mg/kg BID; n = 7), <z:chebi fb="0" ids="40618">aminoguanidine</z:chebi>+<z:chebi fb="0" ids="16467,29952">L-arginine</z:chebi> (300 mg/kg QID; n = 7), <z:chebi fb="0" ids="16467,29952">L-arginine</z:chebi> alone (n = 6), <z:chebi fb="0" ids="15816">D-arginine</z:chebi> alone (n = 6), or vehicle (n = 10) </plain></SENT>
<SENT sid="4" pm="."><plain>Drugs were administered for 3 consecutive days </plain></SENT>
<SENT sid="5" pm="."><plain><z:mpath ids='MPATH_124'>Infarct</z:mpath> volume was determined by image analysis in <z:chebi fb="0" ids="52295">thionin</z:chebi>-stained brain sections 4 days after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>iNOS <z:chebi fb="2" ids="33699">mRNA</z:chebi> was detected with the use of reverse transcription polymerase chain reaction </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: <z:hpo ids='HP_0002637'>Cerebral ischemia</z:hpo> led to iNOS <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression in the affected brain 48 hours after induction of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>Administration of <z:chebi fb="0" ids="40618">aminoguanidine</z:chebi> reduced neocortical <z:mpath ids='MPATH_124'>infarct</z:mpath> volume by 26% (P &lt; .05 versus vehicle, ANOVA and Tukey's test), a reduction that was antagonized by coadministration of <z:chebi fb="0" ids="16467,29952">L-arginine</z:chebi> (P &gt; .05 versus vehicle) </plain></SENT>
<SENT sid="9" pm="."><plain>Administration of <z:chebi fb="0" ids="16467,29952">L-arginine</z:chebi> alone, but not <z:chebi fb="0" ids="15816">D-arginine</z:chebi>, enlarged the <z:mpath ids='MPATH_124'>infarct</z:mpath> by 29% (P &lt; .05) </plain></SENT>
<SENT sid="10" pm="."><plain><z:chebi fb="0" ids="40618">Aminoguanidine</z:chebi> or <z:chebi fb="0" ids="16467,29952">L-arginine</z:chebi> did not influence the increase in water content in the postischemic brain, indicating that the effect on <z:mpath ids='MPATH_124'>infarct</z:mpath> volume is not related to modulation of ischemic <z:hpo ids='HP_0000969'>edema</z:hpo> </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: These results demonstrate that <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> is also associated with iNOS expression in a minimally invasive model of transient <z:chebi fb="70" ids="34342">MCA</z:chebi> occlusion and that iNOS inhibition reduces focal ischemic damage </plain></SENT>
<SENT sid="12" pm="."><plain>The findings support the hypothesis that nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> produced by iNOS contributes to ischemic brain damage and that inhibition of iNOS may be a valuable tool in the management of <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> </plain></SENT>
</text></document>